Advanced search
Start date
Betweenand

Development of a Platform for Dosimetry in Tumor Tissue During the Treatment of Prostate, Neuroendocrine, Thyroid, and Liver Cancers using the Radiopharmaceuticals 90Y-microspheres, 131I-NaI, 131I-MIBG, 177Lu-PSMA, and 177Lu-DOTATATE